IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation
IX001 was safe and highly efficacious in a pancreatic cancer CDX model. Our data support further clinical development of IX001 for HLA-A*11:01 patients with the KRASG12V mutation.
Authors
- Xiaohui Zhang (ORCID: https://orcid.org/0009-0001-9471-4244)
- Hong‐Ming Hu (ORCID: https://orcid.org/0000-0002-2206-3470)
- Anlong Yao (ORCID: https://orcid.org/0009-0007-3642-6352)
- Jiongming Yang (ORCID: https://orcid.org/0009-0007-7168-770X)
- Shuyi Qiu (ORCID: https://orcid.org/0009-0003-4049-034X)
- Dou Wu (ORCID: https://orcid.org/0009-0002-5487-1664)
- Chi Gan (ORCID: https://orcid.org/0009-0007-5616-1507)
- Sizhen Wang (ORCID: https://orcid.org/0000-0002-3184-3313)
- Yonghao Ouyang (ORCID: https://orcid.org/0000-0002-7075-9173)
- Ling Chen (ORCID: https://orcid.org/0009-0002-1289-485X)
- Yimin Chen (ORCID: https://orcid.org/0009-0000-5327-5946)
- Xinbo Wang (ORCID: https://orcid.org/0000-0001-8524-9662)
- Guangrong Yu (ORCID: https://orcid.org/0000-0002-1518-5496)
- Zhufeng Sun (ORCID: https://orcid.org/0009-0004-9886-4356)
- Ran Wei (ORCID: https://orcid.org/0009-0008-9553-1758)
- Yi Xiao (ORCID: https://orcid.org/0009-0009-1705-7517)
- Rongxi Shen (ORCID: https://orcid.org/0000-0002-5723-1876)
- Diling Zhu (ORCID: https://orcid.org/0000-0002-5015-4791)
- Yanzhenzi Dai (ORCID: https://orcid.org/0009-0009-2483-3633)
- Xiaochun Jiang (ORCID: https://orcid.org/0009-0001-9647-036X)
- Lei Huang (ORCID: https://orcid.org/0000-0001-6847-6302)
- Min Li (ORCID: https://orcid.org/0000-0003-2456-8795)
Institutions
- Nanjing General Hospital of Nanjing Military Command (CN)
- Viva Biotech (China) (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3086
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05